Within this area Biotest has developed products for the treatment of Haemophilia A and Haemophilia B.
People with Haemophilia lack certain factors in the blood (coagulation factor VIII or factor IX, respectively) which are vital in the process of blood clot formation and even small external or internal injuries can have serious consequences; which in extreme cases without correct, prompt treatment can be fatal.
Prophylaxis which consists of regular injections of the clotting factor prevents bleeding from even starting. In the cases where patients are not on prophylactic treatment, factor VIII or factor IX preparations are used to stop the bleeding as and when it occurs.
Biotest produces various immunoglobulin products for use in clinical immunology. They are used in the treatment and prophylaxis of disorders of the immune system which are either inherited or acquired. In simple terms, immunoglobulin products replace the patients' missing antibodies and prevent infections caused by various pathogens.
Biotest also produces hyperimmunoglobulins, these are immunoglobulin products with high concentrations of specific antibodies. One example is hepatitis B immunoglobulin – which are administered primarily before, during and directly after liver transplants which have been performed due to hepatitis B infection thus preventing re-infection.
This is described in more detail under “Research and development”.
Intensive care medicine
Biotest manufactures Human Albumin, a product used in intensive care and emergency medicine.